Research

TLR4 as an important target in SARS-COV2 therapy
News

  Rationale COVID-19 may present with mild, moderate, or severe illness. The severe clinical manifestations include severe pneumonia, Acute Respiratory Syndrome (ARDS), sepsis, and septic shock (Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Mar 8]. In: StatPearls-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/). While the virus itself is only moderately pathogenic and about 50% of infected individuals barely notice (“a bad flu”). The others suffer from

TLR4-directed small molecules
Research

Our lab is developing: TLR4 agonists as novel vaccine adjuvants   WE ARE PARTNERS OF THE BACTIVAX PROJECT (EU FUNDED, ETN MARIE CURIE ACTION) FOR THE DEVELOPMENT OF NEW VACCINES DIRECTED AGAINST BACTERIA CAUSING PULMONARY INFECTIONS (RESISTANT BACTERIA SUCH AS MYCOBACTERIA, PSEUDOMONAS, TUBERCOLOSIS) TLR4 antagonists as new drug leads for inflammatory syndromes and SARS.COV2- induced lethality Read our recent paper on the use of TLR4 antagonist to reduce inflammatory bowel